Jane is Chair of cell therapy company Mogrify and CSO of Alchemab Therapeutics. She was an early employee of Cambridge Antibody Technology, which became MedImmune, where she contributed to the development of phage display technology and to the discovery of eight marketed drugs. Jane was Chair of the Board of Directors of the UK BioIndustry Association from 2015-2019, she is a Director of Babraham Bioscience Technologies and Cambridge Enterprise, and she is a member of the Francis Crick Institute’s Translation Advisory Group. In 2019, she was awarded an OBE for services to drug discovery and development and the Scrip Lifetime Achievement Award for contribution to the pharma industry.
Likes
Share It 
